Furthermore, results from clinical trials have shown that the administration of anti-inflammatory agents, such as IL-1 antagonists, in patients with T2D significantly lowered blood glucose levels, as well as CRP, IL-6 and other inflammatory biomarkers (12,13). This evidence concerns the gene CRP and type 2 diabetes mellitus.